TICAM-1 Inhibitors
The class of TICAM-1 inhibitors comprises a diverse array of chemical compounds that exert their inhibitory effects on TICAM-1 either directly or indirectly by modulating key signaling pathways involved in innate immune responses. Amlexanox, for instance, functions as a TICAM-1 inhibitor by targeting the NF-κB signaling pathway. Specifically, it inhibits the IKKε/TBK1 complex, disrupting the phosphorylation and activation of TICAM-1. This direct inhibition interferes with TICAM-1's role in orchestrating antiviral and inflammatory responses, providing a targeted means to modulate innate immunity. BX-795 represents another member of this chemical class, acting as an indirect TICAM-1 inhibitor by targeting TBK1. Through the inhibition of TBK1, BX-795 disrupts the phosphorylation cascade leading to TICAM-1 activation, modulating its function in the induction of type I interferons. This indirect inhibition offers a precise approach to influence TICAM-1 activity within the context of antiviral and inflammatory responses, showcasing the versatility of mechanisms within this chemical class.
BMS-345541, TPCA-1, and IMD-0354 contribute to the class of TICAM-1 inhibitors by targeting the NF-κB signaling pathway and specifically inhibiting components like IKK and IKKβ. These inhibitors disrupt the activation of TICAM-1, providing focused means to modulate its function in innate immune responses. MRT67307, AZD3264, and MRT68921 act as selective inhibitors of TBK1, directly influencing TICAM-1 phosphorylation and downstream signaling events associated with antiviral and inflammatory pathways. GSK583, BX-912, and BAY 11-7082 complete this chemical class, targeting TBK1 and the IKK complex to modulate TICAM-1 activation. Through these specific inhibitory actions, these compounds provide a focused means to interfere with innate immune reactions to pathogenic stimuli. In summary, the chemical class of TICAM-1 inhibitors encompasses a range of compounds with distinct mechanisms, allowing for precise modulation of TICAM-1 and its downstream signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amlexanox | 68302-57-8 | sc-217630 | 10 mg | $160.00 | 2 | |
Amlexanox serves as a TICAM-1 inhibitor by modulating the NF-κB signaling pathway. Specifically, it impedes TICAM-1 activation by inhibiting the IKKε/TBK1 complex, a crucial component in the NF-κB pathway. The inhibition of this complex disrupts downstream signaling events, preventing the phosphorylation and activation of TICAM-1 and thereby modulating its function in innate immune responses. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795 acts as an indirect inhibitor of TICAM-1 by targeting the TBK1 kinase, a key player in the TLR signaling pathway. By inhibiting TBK1, BX-795 disrupts the phosphorylation cascade that activates TICAM-1, thus modulating its function in the induction of type I interferons. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 is a selective inhibitor of the IKK complex, a critical regulator of the NF-κB pathway. By inhibiting IKK, BMS-345541 disrupts the activation of TICAM-1, which is downstream of NF-κB signaling. This inhibition modulates the function of TICAM-1 in mediating cellular responses to pathogenic stimuli and interferes with the downstream signaling events that lead to inflammatory and antiviral responses. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
IMD-0354 functions as an inhibitor of the IKKβ kinase, an essential component of the NF-κB pathway. Through the inhibition of IKKβ, IMD-0354 disrupts the activation of TICAM-1 and modulates its role in the regulation of antiviral and inflammatory responses. This targeted inhibition offers a precise approach to influence TICAM-1 activity and downstream signaling events that contribute to innate immune reactions. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
TPCA-1 (IKK-2 Inhibitor IV), inhibits IKK2. TPCA-1 disrupts the activation of TICAM-1, modulating its function in the induction of type I interferons and other innate immune responses. This specific inhibition offers a focused approach to influence TICAM-1 activity and downstream signaling events associated with antiviral and inflammatory pathways. | ||||||
MRT67307 | 1190378-57-4 | sc-507433 | 10 mg | $234.00 | ||
MRT67307 acts as an inhibitor of TBK1, a kinase crucial for the activation of TICAM-1 in the TLR signaling pathway. By inhibiting TBK1, MRT67307 disrupts the phosphorylation cascade that leads to TICAM-1 activation, modulating its role in the regulation of type I interferons and other innate immune responses. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 acts as an inhibitor of the IKK complex, specifically targeting IKKα and IKKβ. Through the inhibition of these components, BAY 11-7082 disrupts the activation of TICAM-1, modulating its role in NF-κB signaling and downstream events. | ||||||
MRT 68921 | 1190379-70-4 | sc-507429 | 10 mg | $276.00 | ||
MRT68921 functions as a selective inhibitor of TBK1, a kinase crucial for the activation of TICAM-1 in the TLR signaling pathway. By inhibiting TBK1, MRT68921 disrupts the phosphorylation cascade that leads to TICAM-1 activation, modulating its role in the regulation of type I interferons and other innate immune responses. | ||||||